Received Sep 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Y013407 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
HCP reported that a patient had a delay in receiving a second dose of GARDASIL 9.; no additional AE; This spontaneous report was received from a nurse practitioner on 18-Sep-2025, referring to a currently 15-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 10-Apr-2024 (when the patient was 14 years old), the patient was vaccinated with first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9), 0.5 mL, (lot # and expiration date were not reported) as prophylaxis. On 20-Aug-2025, the patient was vaccinated with second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (lot #Y013407, expiration date: 01-Feb-2027), 0.5 ml as prophylaxis. She had a delay in receiving the second dose. There was approximately 16 months in between her first and second dose (Inappropriate schedule of product administration). No symptoms reported. No additional AE (no adverse event).